Form 4: Foghorn Therapeutics Director B. Lynne Parshall Granted 25,000 Stock Options

Foghorn Therapeutics Inc. Director B. Lynne Parshall was granted 25,000 stock options with an exercise price of $4.79 per share, exercisable from June 17, 2026, and expiring on June 16, 2035.

Summary

• B. Lynne Parshall, a Director of Foghorn Therapeutics Inc. (FHTX), acquired 25,000 stock options.
• The transaction date for this acquisition was June 17, 2025.
• Each stock option has an exercise price of $4.79.
• The options become exercisable on June 17, 2026.
• The options are set to expire on June 16, 2035.
• Following this transaction, B. Lynne Parshall directly beneficially owns 25,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: Slightly positive, as the grant of stock options aligns director incentives with shareholder interests, which is generally viewed favorably. However, it's a routine compensation event and not indicative of significant operational news.

Positives

• The grant of stock options to a director aligns their interests with those of shareholders, incentivizing long-term company performance.
• The exercise price of $4.79 per share provides a clear benchmark for future stock performance relative to the grant.

Future Outlook

The stock options granted to Director B. Lynne Parshall are exercisable starting June 17, 2026, and have an expiration date of June 16, 2035, indicating a long-term incentive structure tied to future company performance.

Industry Context

This Form 4 filing is a routine disclosure of an insider equity transaction, common in the biotechnology and pharmaceutical industries where executive and director compensation often includes stock options to align interests with long-term company growth and shareholder value.

Related Party Transactions

• The acquisition of stock options by B. Lynne Parshall, a Director of Foghorn Therapeutics Inc., constitutes a related party transaction as it involves an equity grant from the company to a member of its board.

Stakeholder Impact

• Shareholders: The grant of options to a director can be seen as a positive for shareholders as it aligns the director's financial interests with the company's long-term stock performance.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The reporting person may choose to exercise the stock options at any time between June 17, 2026, and June 16, 2035, assuming the stock price is favorable.

Key Dates

Keywords

Foghorn Therapeutics Inc., FHTX, Stock Option, Director, Equity Grant, Insider Transaction, SEC Form 4, Beneficial Ownership